Navigation Links
SIRION Biotech to Present at April 2020 Virtual Investor Summit: Company to present update on support of its COVID-19 project using its viral vector platforms
Date:4/18/2020

SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene and cell therapy, today announced it will present a company update on its work expediting gene therapy research and advancing drug development during the April 2020 Virtual Investor Summit taking place on April 22 and 23. Dieter Lingelbach, the Company’s Chief Operating Officer, will also provide an update on SIRION’s new initiative to support COVID-19 research. The presentation will take place on Thursday, April 23 at 10:30 a.m. EDT followed by a live Q&A session with registered investors and other conference attendees.

A live webcast of the presentation will be available here. Following the conference, an archived version of the webcast will be available on the company’s website.

Presentation Details
Date: Thursday, April 23, 2020
Time: 10:30 a.m. EDT
Webcast link: https://bit.ly/34GtQjT

About the Virtual Investor Summit
The April 2020 Virtual Investor Summit will take place on April 22nd and 23rd from 10:00am – 3:00pm EDT. The event will feature presentations from public and private companies in multiple industries including life sciences/biotech, infrastructure and transportation. Management teams will present a live audio webcast accompanied by a slide presentation and be available to participate in virtual Q&A sessions immediately following their presentation. Investors, media and interested parties can access the event schedule and individual company webcast details at the event website, virtualinvestorsummit.com.

About SIRION Biotech GmbH
SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST™ has been used in several clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector.

Corporate Contact
Dieter Lingelbach, COO
SIRION Biotech
+49 89-700-96199-14
lingelbach@sirion-biotech.com

Media and Investor Contact USA
Lisa DeScenza
Vice President, Integrated Communications
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com

Read the full story at https://www.prweb.com/releases/sirion_biotech_to_present_at_april_2020_virtual_investor_summit_company_to_present_update_on_support_of_its_covid_19_project_using_its_viral_vector_platforms/prweb17057548.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. COVID-19 Stimulus Grants for Biotech Research Companies Offered by InstantGMP
2. ImStem Biotechnology Announces FDA has Lifted the Clinical Hold on the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
3. Cytonus, the US-based Biotech Platform Company, gains a boost from Strategic Partnership with Europe-based Phoenestra
4. Panitch Schwarze Adds Biotechnology and Life Science Experts to IP team
5. GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells
6. GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells
7. Lifecycle Biotechnologies Introduces High Purity Powder Chemicals Capabilities
8. Lifecycle Biotechnologies Releases 2020 Company Prospectus
9. Lifecycle Biotechnologies Completes Full Integration of Chata Biosystems and VI Plastics
10. Intelligent.com Announces Best Master's in Biotechnology Degree Programs for 2020
11. Biopharma Leaders to Discuss and Share Insights on the Regional Biopharma Ecosystem at LeadingBiotech’s NY/NJ CEO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2020)... SEATTLE, and FT. LAUDERDALE, Fla. (PRWEB) , ... ... ... announces its official launch. The first-of-its-kind category-defining service was started by three teenagers ... to make a change in the world during the time of great need ...
(Date:4/22/2020)... ... , ... RCH Solutions (RCH ), a global provider of Bio-IT computing ... Michael Wlodarczyk as Director of Sales and Business Development. Based out of RCH’s location ... strong presence across the Northeast. , “We continue to see increased demand for specialized ...
(Date:4/18/2020)... MARTINSRIED, Germany and CAMBRIDGE, Mass. (PRWEB) , ... April 16, 2020 ... ... gene delivery technologies for gene and cell therapy, today announced it will present a ... the April 2020 Virtual Investor Summit taking place on April 22 and ...
Breaking Biology News(10 mins):
(Date:4/22/2020)... WEST CHESTER, Ohio (PRWEB) , ... April 21, ... ... availability of Biophen™ FXIII chromogenic method for determination of FXIII. , Aniara Diagnostica, ... has strengthened its commitment to meeting today’s highest standards for product quality and ...
(Date:4/7/2020)... LA JOLLA, Calif. (PRWEB) , ... April 06, 2020 , ... ... insight into their future children, reached 200,000 SneakPeek Early Gender DNA Tests ... , “ SneakPeek was launched as an ecommerce product, where a mom could ...
(Date:4/1/2020)... ... March 30, 2020 , ... A joint venture between mobile ... earlier this year to bring telehealth to various government agencies, has now focused ... officials are currently?awaiting an Emergency Use Authorization (EUA) waiver from the FDA?to?perform?AI?testing in ...
(Date:4/1/2020)... Conn. (PRWEB) , ... March 31, 2020 , ... ... Science, Inc. (P2) announce the signing of a Joint Development Agreement that ... , Bedoukian Research, Inc. is a global leader in the supply of high-quality ...
Breaking Biology Technology: